High incidence of c-jun kinase activity in 2/relapsed acute leukemia: role in mrp-mediated drug resistance?

Larry Cripe, O. S. Burgess, L. Tanzer, P. Kneebpne, E. A. Williamson, A. S. Kraft, R. E. Moore, H. Boswell

Research output: Contribution to journalArticle

Abstract

Multidrug resistance in leukemia has been attributed to expression of the p-glycoprotein, product of the mdrl gene, or to high expression of bcl-2, an anti-apoptotic effector protein. However, expression of these two effectors is highly restricted within certain leukcmic FAB types, and their frequency does not adequately explain many cases of treatment failure. We hypothesized that failure of induction therapy with cytosine arabinoside plus anthracycline may more commonly follow glutathione (GSH)-dependent drug export by the multidrug resistance-related protein (MRP), and that MRP expression, expression of enzymes such as glutathione-S-transferase, and also the rate-limiting enzyme for GSH synthesis (GGCS), may be coordinately induced in leukemia by high activity of the jun-N-terminal kinase (INK). JNK regulates by posttranslational modification on the c-jun protein, c-jun/AP-1 transactivation of the c-jun, G-S-transferase, and possibly MRP and GGCS, gene(s) in a positive autoregulatory loop. We analyzed JNK kinase activity from cell lysates on GST-c-jun substrate followed by SDS-PAGE and autoradiography as well as c-jun protein expresssion by immunoblot. We compared these activities with expression levels of mRNA for MRP and mdrl, determined by semiquantitative RT-PCR, within 15 cases of acute leukemia (12 ANLL, 3 CML BC). Six cases were secondary or relapsed leukemia. JNK activity assay was positive in 8 of 13 cases tested. Of these, six were the secondary or relapsed disease specimens. High levels of MRP mRNA was noted in 7/11 of cases subjected to analysis, and there was agreement with JNK activity status in 7/11 cases overall. All secondary/relapsed leukemias tested in both assays demonstrated JNK activity and MRP expression except one, whose JNK kinase activity was absent, but cellular c-jun protein was present. This experience suggests there is a functional link between JNK/c-jun expression and associated treatment failure of high-risk leukemias that are induced to express MRP. It is tempting to postulate that c-jun/AP-1-mediated transcriptional activation of MRP gene expression, and augmented synthesis of GSH driven by AP-1-dependent GGCS, is a dominant cause of treatment failure in acute leukemia, especially in a significant proportion of cases that fail to express measurable mdr1.

Original languageEnglish
Pages (from-to)854
Number of pages1
JournalExperimental Hematology
Volume25
Issue number8
StatePublished - 1997

Fingerprint

P-Glycoproteins
Drug Resistance
Leukemia
Phosphotransferases
Incidence
Proto-Oncogene Proteins c-jun
Transcription Factor AP-1
Treatment Failure
MAP Kinase Kinase 4
Transcriptional Activation
Messenger RNA
Apoptosis Regulatory Proteins
Anthracyclines
Cytarabine
Multiple Drug Resistance
Enzymes
Post Translational Protein Processing
Transferases
Glutathione Transferase
Autoradiography

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

High incidence of c-jun kinase activity in 2/relapsed acute leukemia : role in mrp-mediated drug resistance? / Cripe, Larry; Burgess, O. S.; Tanzer, L.; Kneebpne, P.; Williamson, E. A.; Kraft, A. S.; Moore, R. E.; Boswell, H.

In: Experimental Hematology, Vol. 25, No. 8, 1997, p. 854.

Research output: Contribution to journalArticle

Cripe, L, Burgess, OS, Tanzer, L, Kneebpne, P, Williamson, EA, Kraft, AS, Moore, RE & Boswell, H 1997, 'High incidence of c-jun kinase activity in 2/relapsed acute leukemia: role in mrp-mediated drug resistance?', Experimental Hematology, vol. 25, no. 8, pp. 854.
Cripe, Larry ; Burgess, O. S. ; Tanzer, L. ; Kneebpne, P. ; Williamson, E. A. ; Kraft, A. S. ; Moore, R. E. ; Boswell, H. / High incidence of c-jun kinase activity in 2/relapsed acute leukemia : role in mrp-mediated drug resistance?. In: Experimental Hematology. 1997 ; Vol. 25, No. 8. pp. 854.
@article{35f4286af0de4eaca7b239969c209d65,
title = "High incidence of c-jun kinase activity in 2/relapsed acute leukemia: role in mrp-mediated drug resistance?",
abstract = "Multidrug resistance in leukemia has been attributed to expression of the p-glycoprotein, product of the mdrl gene, or to high expression of bcl-2, an anti-apoptotic effector protein. However, expression of these two effectors is highly restricted within certain leukcmic FAB types, and their frequency does not adequately explain many cases of treatment failure. We hypothesized that failure of induction therapy with cytosine arabinoside plus anthracycline may more commonly follow glutathione (GSH)-dependent drug export by the multidrug resistance-related protein (MRP), and that MRP expression, expression of enzymes such as glutathione-S-transferase, and also the rate-limiting enzyme for GSH synthesis (GGCS), may be coordinately induced in leukemia by high activity of the jun-N-terminal kinase (INK). JNK regulates by posttranslational modification on the c-jun protein, c-jun/AP-1 transactivation of the c-jun, G-S-transferase, and possibly MRP and GGCS, gene(s) in a positive autoregulatory loop. We analyzed JNK kinase activity from cell lysates on GST-c-jun substrate followed by SDS-PAGE and autoradiography as well as c-jun protein expresssion by immunoblot. We compared these activities with expression levels of mRNA for MRP and mdrl, determined by semiquantitative RT-PCR, within 15 cases of acute leukemia (12 ANLL, 3 CML BC). Six cases were secondary or relapsed leukemia. JNK activity assay was positive in 8 of 13 cases tested. Of these, six were the secondary or relapsed disease specimens. High levels of MRP mRNA was noted in 7/11 of cases subjected to analysis, and there was agreement with JNK activity status in 7/11 cases overall. All secondary/relapsed leukemias tested in both assays demonstrated JNK activity and MRP expression except one, whose JNK kinase activity was absent, but cellular c-jun protein was present. This experience suggests there is a functional link between JNK/c-jun expression and associated treatment failure of high-risk leukemias that are induced to express MRP. It is tempting to postulate that c-jun/AP-1-mediated transcriptional activation of MRP gene expression, and augmented synthesis of GSH driven by AP-1-dependent GGCS, is a dominant cause of treatment failure in acute leukemia, especially in a significant proportion of cases that fail to express measurable mdr1.",
author = "Larry Cripe and Burgess, {O. S.} and L. Tanzer and P. Kneebpne and Williamson, {E. A.} and Kraft, {A. S.} and Moore, {R. E.} and H. Boswell",
year = "1997",
language = "English",
volume = "25",
pages = "854",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - High incidence of c-jun kinase activity in 2/relapsed acute leukemia

T2 - role in mrp-mediated drug resistance?

AU - Cripe, Larry

AU - Burgess, O. S.

AU - Tanzer, L.

AU - Kneebpne, P.

AU - Williamson, E. A.

AU - Kraft, A. S.

AU - Moore, R. E.

AU - Boswell, H.

PY - 1997

Y1 - 1997

N2 - Multidrug resistance in leukemia has been attributed to expression of the p-glycoprotein, product of the mdrl gene, or to high expression of bcl-2, an anti-apoptotic effector protein. However, expression of these two effectors is highly restricted within certain leukcmic FAB types, and their frequency does not adequately explain many cases of treatment failure. We hypothesized that failure of induction therapy with cytosine arabinoside plus anthracycline may more commonly follow glutathione (GSH)-dependent drug export by the multidrug resistance-related protein (MRP), and that MRP expression, expression of enzymes such as glutathione-S-transferase, and also the rate-limiting enzyme for GSH synthesis (GGCS), may be coordinately induced in leukemia by high activity of the jun-N-terminal kinase (INK). JNK regulates by posttranslational modification on the c-jun protein, c-jun/AP-1 transactivation of the c-jun, G-S-transferase, and possibly MRP and GGCS, gene(s) in a positive autoregulatory loop. We analyzed JNK kinase activity from cell lysates on GST-c-jun substrate followed by SDS-PAGE and autoradiography as well as c-jun protein expresssion by immunoblot. We compared these activities with expression levels of mRNA for MRP and mdrl, determined by semiquantitative RT-PCR, within 15 cases of acute leukemia (12 ANLL, 3 CML BC). Six cases were secondary or relapsed leukemia. JNK activity assay was positive in 8 of 13 cases tested. Of these, six were the secondary or relapsed disease specimens. High levels of MRP mRNA was noted in 7/11 of cases subjected to analysis, and there was agreement with JNK activity status in 7/11 cases overall. All secondary/relapsed leukemias tested in both assays demonstrated JNK activity and MRP expression except one, whose JNK kinase activity was absent, but cellular c-jun protein was present. This experience suggests there is a functional link between JNK/c-jun expression and associated treatment failure of high-risk leukemias that are induced to express MRP. It is tempting to postulate that c-jun/AP-1-mediated transcriptional activation of MRP gene expression, and augmented synthesis of GSH driven by AP-1-dependent GGCS, is a dominant cause of treatment failure in acute leukemia, especially in a significant proportion of cases that fail to express measurable mdr1.

AB - Multidrug resistance in leukemia has been attributed to expression of the p-glycoprotein, product of the mdrl gene, or to high expression of bcl-2, an anti-apoptotic effector protein. However, expression of these two effectors is highly restricted within certain leukcmic FAB types, and their frequency does not adequately explain many cases of treatment failure. We hypothesized that failure of induction therapy with cytosine arabinoside plus anthracycline may more commonly follow glutathione (GSH)-dependent drug export by the multidrug resistance-related protein (MRP), and that MRP expression, expression of enzymes such as glutathione-S-transferase, and also the rate-limiting enzyme for GSH synthesis (GGCS), may be coordinately induced in leukemia by high activity of the jun-N-terminal kinase (INK). JNK regulates by posttranslational modification on the c-jun protein, c-jun/AP-1 transactivation of the c-jun, G-S-transferase, and possibly MRP and GGCS, gene(s) in a positive autoregulatory loop. We analyzed JNK kinase activity from cell lysates on GST-c-jun substrate followed by SDS-PAGE and autoradiography as well as c-jun protein expresssion by immunoblot. We compared these activities with expression levels of mRNA for MRP and mdrl, determined by semiquantitative RT-PCR, within 15 cases of acute leukemia (12 ANLL, 3 CML BC). Six cases were secondary or relapsed leukemia. JNK activity assay was positive in 8 of 13 cases tested. Of these, six were the secondary or relapsed disease specimens. High levels of MRP mRNA was noted in 7/11 of cases subjected to analysis, and there was agreement with JNK activity status in 7/11 cases overall. All secondary/relapsed leukemias tested in both assays demonstrated JNK activity and MRP expression except one, whose JNK kinase activity was absent, but cellular c-jun protein was present. This experience suggests there is a functional link between JNK/c-jun expression and associated treatment failure of high-risk leukemias that are induced to express MRP. It is tempting to postulate that c-jun/AP-1-mediated transcriptional activation of MRP gene expression, and augmented synthesis of GSH driven by AP-1-dependent GGCS, is a dominant cause of treatment failure in acute leukemia, especially in a significant proportion of cases that fail to express measurable mdr1.

UR - http://www.scopus.com/inward/record.url?scp=33748622317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748622317&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748622317

VL - 25

SP - 854

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 8

ER -